KR100392904B1 - Composition containing egg yolk antibody, and food containing it - Google Patents
Composition containing egg yolk antibody, and food containing it Download PDFInfo
- Publication number
- KR100392904B1 KR100392904B1 KR10-2001-0001763A KR20010001763A KR100392904B1 KR 100392904 B1 KR100392904 B1 KR 100392904B1 KR 20010001763 A KR20010001763 A KR 20010001763A KR 100392904 B1 KR100392904 B1 KR 100392904B1
- Authority
- KR
- South Korea
- Prior art keywords
- antibody
- egg
- weight
- composition
- food
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 210000002969 egg yolk Anatomy 0.000 title claims abstract description 34
- 235000013305 food Nutrition 0.000 title claims abstract description 24
- 102000002322 Egg Proteins Human genes 0.000 title description 18
- 108010000912 Egg Proteins Proteins 0.000 title description 18
- 235000013345 egg yolk Nutrition 0.000 title description 18
- 239000000843 powder Substances 0.000 claims abstract description 24
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000005487 catechin Nutrition 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 18
- 229950001002 cianidanol Drugs 0.000 claims abstract description 18
- 239000008213 purified water Substances 0.000 claims abstract description 17
- 235000000346 sugar Nutrition 0.000 claims abstract description 13
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 12
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 10
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 6
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 6
- 206010019375 Helicobacter infections Diseases 0.000 claims abstract description 5
- 241000590002 Helicobacter pylori Species 0.000 claims description 18
- 229940037467 helicobacter pylori Drugs 0.000 claims description 18
- 241000589989 Helicobacter Species 0.000 abstract description 2
- 235000013601 eggs Nutrition 0.000 description 46
- 108010067454 caseinomacropeptide Proteins 0.000 description 18
- 239000000243 solution Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 208000007882 Gastritis Diseases 0.000 description 8
- 208000007107 Stomach Ulcer Diseases 0.000 description 8
- 238000005238 degreasing Methods 0.000 description 8
- 208000000718 duodenal ulcer Diseases 0.000 description 8
- 201000005917 gastric ulcer Diseases 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 229930091371 Fructose Natural products 0.000 description 7
- 239000005715 Fructose Substances 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 235000013618 yogurt Nutrition 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 150000008163 sugars Chemical class 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108010011756 Milk Proteins Proteins 0.000 description 4
- 102000014171 Milk Proteins Human genes 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 235000021239 milk protein Nutrition 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010046334 Urease Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013350 formula milk Nutrition 0.000 description 3
- 235000020688 green tea extract Nutrition 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 150000001765 catechin Chemical class 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000000249 desinfective effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 229940030275 epigallocatechin gallate Drugs 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 229940094952 green tea extract Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000021056 liquid food Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241001333951 Escherichia coli O157 Species 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001025070 Philophyllum Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000006270 Proton Pumps Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 108010017898 Shiga Toxins Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- RSAZYXZUJROYKR-UHFFFAOYSA-N indophenol Chemical compound C1=CC(O)=CC=C1N=C1C=CC(=O)C=C1 RSAZYXZUJROYKR-UHFFFAOYSA-N 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/54—Proteins
- A23V2250/542—Animal Protein
- A23V2250/5434—Immunoglobulines
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Meat, Egg Or Seafood Products (AREA)
Abstract
본 발명은 헬리코박터 필로리 항체 함유 탈지 난황 분말에, 조성물 총 중량에 대하여 0.02-0.1 중량%의 카테킨, 0.1-1.0 중량%의 당단백질(GMP), 5-10 중량%의 당류, 5-10 중량%의 당알콜, 5-20 중량% 인지질 및 정제수를 배합하여 이루어지는, 헬리코박터 필로리 감염 예방용 계란 항체 함유 조성물, 및 이를 함유하는 식품에 관한 것이다.The present invention is applied to Helicobacter Philolyli antibody-containing skim yolk powder, 0.02-0.1% by weight of catechin, 0.1-1.0% by weight glycoprotein (GMP), 5-10% by weight of sugar, 5-10% by weight relative to the total weight of the composition The present invention relates to an egg antibody-containing composition for preventing Helicobacter pylori infection, and a food containing the same, comprising a% sugar alcohol, 5-20% by weight phospholipid and purified water.
Description
본 발명은 계란 항체 함유 조성물 및 이를 함유하는 식품에 관한 것이다.The present invention relates to an egg antibody-containing composition and a food containing the same.
헬리코박터 필로리는 강산성 조건 하에 있는 위 내에서도 생존하는 경우가 있을 뿐 아니라 위궤양, 십이지장궤양과 같은 소화성궤양 및 만성위염의 발병과 재발에 깊숙히 관여하고 있는 것으로 알려져 있다. 또한, 위암과의 인과관계에 대해서도 역학조사 혹은 동물실험을 통하여 그 관계를 규명하는 연구가 많이 보고되고 있다.Helicobacter pylori is known to not only survive in the stomach under strong acidic conditions but also to be involved in the development and recurrence of peptic ulcers such as gastric ulcer and duodenal ulcer and chronic gastritis. In addition, many studies on the causal relationship with gastric cancer have been reported through epidemiological investigations or animal experiments.
소화성궤양 환자는 대부분의 경우에 헬리코박터 필로리 감염이 확인되고 있으며, 이 균을 제균하는 방법에 따라 2년 이내의 재발율이 10%이내로 격감하는 결과가 보고되고 있어, 효과적인 제균 방법은 더욱더 절실한 과제로 인식되고 있다.In most cases, pneumatic ulcer patients have been identified as Helicobacter pylori infection, and the method of disinfecting the bacterium has been reported to reduce the recurrence rate within 10% within 2 years. It is recognized.
현재 세계적으로 통용되고 있는 치료 방법으로는, 소화궤양의 치료에 사용되는 강력한 산분비억제제인 프로톤펌프 제재와 항생물질 2 종류(크라리스로마이신과 아모키시린 혹은 메토로니다솔)를 병용한 3 종류 병용 치료법이 일반치료법으로서 널리 실시되고 있다. 이 3 종류의 병용 치료법의 제균율은 80∼90% 정도이나, 이 방법은 항생물질을 다량 사용하기 때문에 부작용의 문제와 내성균이 생길 수 있는 문제를 안고 있다.Currently used treatments around the world include a combination of proton pumps, which are powerful acid secreting agents used in the treatment of peptic ulcers, and two kinds of antibiotics (Criraceromycin and Amoxicillin or Metronidasol). Kind combination therapy is widely practiced as a general therapy. The bactericidal rate of these three types of combination therapy is about 80-90%, but this method uses a large amount of antibiotics, which poses problems of side effects and resistant bacteria.
이러한 문제를 해결하기 위해 천연물에 의한 예방 및 제균방법이 발명되고 있다. 일본 특허 공개 공보 특개평 10-287585에는 헬리코박터 필로리에 특이적인 난황유래의 항체를 함유한 식품을 이용함으로서 헬리코박터 필로리의 효과적인 제균 방법이 개시되어 있다.In order to solve this problem, methods for preventing and disinfecting by natural products have been invented. Japanese Patent Laid-Open No. Hei 10-287585 discloses an effective bactericidal method of Helicobacter pylori by using a food containing yolk-derived antibodies specific for Helicobacter pylori.
일반적으로 소화기관감염증 등에서 가장 먼저 일어나는 단계는 기관 또는 조직표층에 대하여 병원성 바이러스나 병원세균이 부착하는 것이다. 이러한 감염증의 병원체를 항원으로 하여 제조된 특이항체는, 대응하는 병원체와 결합하여 병원체가 소화기관 상피세포 등에 점착하는 것을 저해함으로서 감염증의 예방과 치료에 효과가 있는 것으로 인식되고 있다.In general, the first step in gastrointestinal infections is the attachment of pathogenic viruses or pathogens to the organ or tissue surface. It is recognized that a specific antibody produced using such an infectious agent as an antigen is effective in preventing and treating an infectious disease by binding to a corresponding pathogen and inhibiting the pathogen from adhering to digestive organ epithelial cells.
계란유래의 항체는 또한 대량 제조에 적합하여 실제 생산에 있어서도 효과적이지만, 난황 유래 항체는 활성을 갖는 단백질로서 그 활성은 항체의 선단부분에있는 초 가변부의 구조에서 유래되므로, 초가변부의 구조변화(단백질의 변성)가 있는 경우에는 항체의 활성을 고려할 때 매우 치명적이다.Egg-derived antibodies are also suitable for mass production and effective in actual production, but egg yolk-derived antibodies are active proteins whose activity is derived from the structure of the hypervariable region at the tip of the antibody. Protein denaturation) is very fatal considering the activity of the antibody.
일반적으로 단백질은 열, pH 등에 약한 것으로 알려져 있으므로, 단백질인 상기 난황 유래 항체 역시 직접 변성에 관련있는 가열, 산성 조건 하에서의 사용이 매우 곤란하다.In general, since proteins are known to be weak in heat, pH, etc., the yolk-derived antibody, which is a protein, is also very difficult to use under heating and acidic conditions related to direct denaturation.
따라서 상기 난황 유래 항체는 열안정성, pH 안정성, 용해성, 분산성 등이 낮고, 항체함유난황 자체를 액상식품에 응용할 경우 식품형태에서 분리현상이 나타나므로 식품에 응용하는 것이 곤란하다.Therefore, the yolk-derived antibody has low thermal stability, pH stability, solubility, dispersibility, etc., and when the antibody-containing yolk itself is applied to the liquid food, it is difficult to apply the food to the food because the separation occurs in the food form.
한편, 녹차의 주성분인 카테킨은 몇가지 우수한 생리 활성을 가지고 있는 것으로 알려져 있다. 녹차 추출물 중에서도 카테킨류(Epigallocatechin gallate, gallocatechin gallte)는 장관출혈성 대장균 O-157 H7 및 베로독소의 생산을 약화시키는 활성, 생체내항균활성, 암의 예방, 장내균총의 개선 효과 등의 우수한 생리활성을 갖는 것으로 보고되고 있다.On the other hand, catechin, the main component of green tea, is known to have some excellent physiological activities. Among the green tea extracts, catechins (Epigallocatechin gallate, gallocatechin gallte) have an excellent physiological activity such as weakening the production of intestinal hemorrhagic E. coli O-157 H7 and vero toxin, in vivo antibacterial activity, prevention of cancer, and improvement of intestinal flora. It is reported to have.
또한 유단백질 유래의 당단백질인 글리코마크로펩티드(Glycomacropeptide, GMP)는 κ-카제인의 친수성 부분으로, 장내 유산균의 증식활성, 콜레라독소의 중화활성 등 많은 생리활성이 보고되고 있는데, 이러한 녹차 추출물과 유단백질 유래의 GMP는 식품에 첨가하는 경우 용해성이 낮아 첨가량이 제한되는 문제가 있어 식품에의 응용이 어렵다는 문제점이 있다.Glycomacropeptide (GMP), a glycoprotein derived from milk protein, is a hydrophilic part of κ-casein, and many physiological activities, such as proliferation activity of intestinal lactic acid bacteria and neutralization activity of cholera toxin, have been reported. GMP has a problem in that it is difficult to be applied to food because it has a problem that the amount of solubility is low when added to food.
상기의 문제점을 해결하기 위한 본 발명은 계란 유래 항체에 녹차 추출물,GMP, 당류, 당알콜, 인지질을 일정 비율 첨가함으로써 위염, 위궤양 및 십이지장궤양 등의 예방 효과를 상승시킬 수 있을 뿐 아니라 열, pH 등에도 안정하여 식품에 응용하기에 적합한, 내열성, 용해성 및 가공성이 향상된 계란 항체 함유 조성물 및 이러한 조성물을 함유하는 식품을 제공하는 것을 목적으로 한다.The present invention for solving the above problems by adding a certain ratio of green tea extract, GMP, sugars, sugar alcohol, phospholipid to the egg-derived antibody can not only increase the protective effect of gastritis, gastric ulcer and duodenal ulcer, but also heat, pH, etc. It is an object of the present invention to provide an egg antibody-containing composition having improved heat resistance, solubility and processability and suitable for application to food, and a food containing the composition.
도 1은 계란 항체 함유 조성물(1) 및 계란 항체 함유 조성물(2), (3), (4)의 시궁쥐의 헬리코박터 필로리에 대한 제균효과를 시험한 그래프,1 is a graph of the bactericidal effect on the Helicobacter pylori of the rats of the egg antibody-containing composition (1) and egg antibody-containing composition (2), (3), (4),
도 2는 탈지난황액, 계란항체함유 조성물(1) 및 계란항체함유 조성물(2)의 용해성 및 내열성을 비교한 그래프,2 is a graph comparing the solubility and heat resistance of the defatted yolk solution, egg antibody-containing composition (1) and egg antibody-containing composition (2),
도 3은 표 3의 시료에 대한 우레아제 함량을 통하여 헬리코박터 필로리에 대한 접착 억제 효과를 도시한 그래프.Figure 3 is a graph showing the effect of inhibiting adhesion to Helicobacter pylori through the urease content for the samples of Table 3.
상기 목적을 달성하기 위하여, 본 발명에 따르면, 헬리코박터 필로리(Helicobacter pylori) 항체 함유 탈지 난황 분말에, 조성물 총 중량에 대하여 0.02-0.1 중량%의 카테킨, 0.1-1.0 중량%의 당단백질(GMP), 5-10 중량%의 당류, 5-10 중량%의 당알콜, 5-20 중량% 인지질 및 정제수를 배합하여 이루어지는, 헬리코박터 필로리 감염 예방용 계란 항체 함유 조성물, 및 이를 함유하는 식품이 제공된다.In order to achieve the above object, according to the present invention, Helicobacter pylori antibody-containing skim yolk powder, 0.02-0.1% by weight of catechin, 0.1-1.0% by weight glycoprotein (GMP) based on the total weight of the composition There is provided an egg antibody-containing composition for preventing Helicobacter pylori infection, comprising 5-10 wt% sugar, 5-10 wt% sugar alcohol, 5-20 wt% phospholipid and purified water, and a food containing the same.
이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명에서 사용되는 항체함유 난황은 분말형태로 탈지하여 이용하는 것이 바람직하다.The antibody-containing egg yolk used in the present invention is preferably used by degreasing in powder form.
고순도 녹차 추출물인 카테킨은 약 65%이상의 에피갈로카테킨(Egcg; Epigallocatechin gallate)을 주성분으로 하는 것이 더 효과적이다. 카테킨은 조성물의 총 중량에 대하여 0.1% 초과 첨가하면 고미가 느껴져 풍미에 영향을 미치고, 0.02% 미만으로 첨가하면 효과가 없으므로, 0.02∼0.1중량%으로 조정하는 것이 바람직하며, 이를 통하여 항산화 효과도 기대할 수 있다.Catechin, a high-purity green tea extract, is more effective with epigallocatechin gallate (Egcg) of about 65% or more. If catechin is added more than 0.1% to the total weight of the composition, the taste is felt and affects the flavor. If it is added less than 0.02%, the catechin is preferably adjusted to 0.02 to 0.1% by weight. Can be.
또한, 본 발명에서의 유단백질 유래의 당단백질인 GMP는 특별히 한정하는 것은 아니나, 이온교환수지법, 막 분리법 등 공지의 방법을 이용하여 분리정제 한 것으로, GMP가 총 유단백질 중 약 70% 이상 함유된 것을 사용하는 것이 바람직한데 이는 고순도일수록 효과가 우수하기 때문이다. 또한 씨알산의 함량이 높을수록 좋다. GMP는 조성물 총 중량에 대하여 0.1 내지 1.0 중량%로 첨가하는 것이 바람직한데, 0.1 중량% 미만이면 첨가의 효과가 없고, 1.0 중량% 초과이면 용해성에 문제가 있다.In addition, GMP, which is a glycoprotein derived from a milk protein in the present invention is not particularly limited, but is separated and purified by a known method such as an ion exchange resin method or a membrane separation method, and GMP is contained in about 70% or more of the total milk protein. It is preferable to use it because the higher the purity, the better the effect. In addition, the higher the content of sialic acid is better. GMP is preferably added in an amount of 0.1 to 1.0% by weight based on the total weight of the composition. If it is less than 0.1% by weight, there is no effect of addition, and if it is more than 1.0% by weight, there is a problem in solubility.
본 발명에서 당류 및 당알콜은 특별하게 한정하는 것은 아니나, 당류로는 고과당이나 수크로오스를 사용하는 것이 바람직하고, 당알콜로는 슈가 에스테르(Sugar ester)를 사용하는 것이 바람직하다. 그 중에서도 당류로는 고과당을 사용하고 당알콜로는 솔비톨을 사용하는 것이 특히 바람직하다. 당류의 첨가량은 조성물 총중량의 5-10중량%인 것이 바람직하고, 당알콜의 첨가량은 조성물 총중량의 5-10중량%인 것이 바람직하다. 당류와 당알콜을 5중량% 미만으로 첨가하면 첨가의 효과가 없고, 10중량%를 초과하는 경우에는 당도가 너무 높아지기 때문이다.In the present invention, sugars and sugar alcohols are not particularly limited, but it is preferable to use high fructose or sucrose as sugars, and sugar esters as sugar alcohols. Among them, it is particularly preferable to use high fructose as the sugar and sorbitol as the sugar alcohol. The amount of sugar added is preferably 5-10% by weight of the total weight of the composition, and the amount of sugar alcohol is preferably 5-10% by weight of the total weight of the composition. This is because when the sugar and the sugar alcohol are added in less than 5% by weight, there is no effect of addition, and when it exceeds 10% by weight, the sugar content becomes too high.
또한 인지질로는 대두인지질(레시틴), 난황레시틴 등을 사용할 수 있으며, 난황유래의 고순도 인지질이 풍미나 가공성에서 더욱 바람직하다. 그 첨가량은 조성물 총 중량에 대하여 5-20 중량%가 바람직한데, 5중량% 미만이면 지나치게 묽어지고 20중량%를 초과하면 점성이 지나치게 높아지기 때문이다.In addition, soybean phospholipid (lecithin), egg yolk lecithin and the like may be used, and high purity phospholipid derived from egg yolk is more preferable in flavor and processability. The addition amount is preferably 5-20% by weight based on the total weight of the composition, since less than 5% by weight becomes too thin and more than 20% by weight becomes too viscous.
본 발명에 따른 계란 항체 함유 조성물은 예를 들어 회전식 교반날개가 붙은 교반기 등으로 당류, 당알콜, 인지질 등을 첨가한 후 교반하고, 여기에 물, 카테킨 및 GMP를 순서적으로 배합한 후 거품이 일지 않도록 교반하여 배합하는 것이 바람직하다.For example, the egg antibody-containing composition according to the present invention is added with sugars, sugar alcohols, phospholipids, etc., using a stirrer with a rotary stir blade, and then stirred, followed by mixing water, catechin, and GMP in this order and foaming. It is preferable to mix | blend so that it may mix.
헬리코박터 필로리 항체 함유 탈지 난황에 카테킨 및 유단백질 유래의 당단백질을 배합함으로써, 헬리코박터 필로리 감염의 제1단계인 접착에 대한 저해 효과가 향상되고, 고순도의 인지질 및 당류를 첨가함으로써 식품첨가 프로세스에서 큰 문제가 되는 내열성, 내산성이 뚜렷하게 향상된다.By combining glycoproteins derived from catechins and milk proteins with skim yolk containing Helicobacter pylori, the inhibitory effect on adhesion, which is the first stage of Helicobacter pylori infection, is improved, and high purity phospholipids and sugars are added to the food addition process. The heat resistance and acid resistance which are problematic become markedly improved.
또한 본 발명에 따른 조성물은 식품첨가 시 내열성, 용해성, 분산성이 향상되므로, 상기와 같은 본 발명의 계란 항체 함유 조성물을 첨가하여 식품을 제조할 수 있다.In addition, since the composition according to the present invention improves heat resistance, solubility, and dispersibility when food is added, food can be prepared by adding the egg antibody-containing composition of the present invention as described above.
상기 식품의 예로는, 유제품, 청량 음료수 등의 각종 음료수, 건강보조식품류 등이 있으나, 이에 한정되는 것은 아니다.Examples of the food include, but are not limited to, various beverages such as dairy products, soft drinks, and health supplement foods.
본 발명에서 유제품이라 함은 특별히 한정하는 것은 아니나, 예를 들면 우유(생유, 가공유), 육아용 조제분유, 요구르트, 드링크요구르트, 아이스크림, 탈지분유, 혼합분유 등을 들 수 있다.In the present invention, the term "dairy product" is not particularly limited. Examples thereof include milk (fresh milk, processed milk), baby formula, yogurt, drink yogurt, ice cream, skim milk powder, mixed milk powder, and the like.
본 발명의 계란항체함유 조성물을 유제품, 각종음료수 및 건강보조식품에 첨가하는 경우는, 그 첨가량은 특별히 한정하는 것은 아니나 제품 총중량에 대하여 1 중량% 이상인 것이 바람직하다.When the egg antibody-containing composition of the present invention is added to dairy products, various beverages, and health supplements, the addition amount is not particularly limited but is preferably 1% by weight or more based on the total weight of the product.
하기 실시예는 본 발명을 설명하기 위한 것으로, 본 발명이 이에 한정되는 것은 아니다.The following examples are provided to illustrate the present invention, but the present invention is not limited thereto.
(실시예 1)(Example 1)
(1) 항원의 제조(1) Preparation of Antigen
헬리코박터 필로리 임상분리주를 7% 마탈섬유혈액을 함유한 한천배지에 37℃, 4일간 배양하였다(10% CO2, 10% 공기, 가습). 배양 후 생성된 콜로니를 떼어내어 생리식염수에 현탁하고, 현탁액에 0.5%(v/v)가 되게 포르말린을 가하고, 실온 18시간 방치하여 균체의 불활성처리를 행하였다.Helicobacter pylori clinical isolates were incubated for 4 days at 37 ° C. in agar medium containing 7% metal fiber (10% CO 2 , 10% air, humidification). After incubation, the resulting colonies were removed, suspended in physiological saline, formalin was added to the suspension at 0.5% (v / v), and left at room temperature for 18 hours to inactivate the cells.
다음에 균체를 3,000×g, 10분간 원심분리하여 모으고, 생리식염수로 3회 세정하였다. 균체를 생리식염수에 분산시킨 후, 히스코트론으로 균질화하고, 파장 660nm에서 흡광도를 0.8으로 조제하여 항원액 A로 하였다.Next, the cells were collected by centrifugation at 3,000 × g for 10 minutes and washed three times with physiological saline. The cells were dispersed in physiological saline, homogenized with histotron, and the absorbance was 0.8 at a wavelength of 660 nm to obtain antigen solution A.
(2)면역 난황의 제조(2) Production of immune egg yolk
산란계(휴이트레그혼)에 항원액을 1마리당 1ml 근육 주사하였다. 면역은 매주 1회, 합계 4회 반복한 후, 항체가의 유지를 목적으로 1개월마다 1회의 면역을 행하였다.1 ml of antigen was injected per egg into the laying hens (Heytreghorn). Immunization was repeated once a week, four times in total, and immunization was performed once every month for the purpose of maintaining the antibody titer.
계란난황 중의 특이 항체가는, 미세적정법에 의해 응집 항체가를 측정하였다. 2주마다 모은 계란에서 난황을 분리하고, 난황1g과 λ-카라기난 수용액(1.5% w/v) 9ml을 혼화하고, 실온에서 30분간 방치 후, 1,000×g, 10분간 원심분리를 행하고, 특이적 항체를 함유한 난황수용성 단백분획을 얻어 시료액으로 하였다.The specific antibody titer in egg yolk was measured by aggregate titer by microtiter method. Egg yolk is separated from the eggs collected every two weeks, 1 g of yolk and 9 ml of lambda -carrageenan aqueous solution (1.5% w / v) are mixed and left at room temperature for 30 minutes, followed by centrifugation at 1,000 × g for 10 minutes. An egg yolk soluble protein fraction containing an antibody was obtained to prepare a sample solution.
시료액을 생리적 인산완충액 pH 7.4(이하 PBS라 함)으로 2배 희석하여 검액으로 하였다.The sample solution was diluted twice with physiological phosphate buffer pH 7.4 (hereinafter referred to as PBS) to obtain a sample solution.
각 검액 50㎕과 항원액 50㎕을 마이크로플레이트 중에 혼화하고, 37℃, 24시간 정치하여 응고 유무를 조사하였다. 항원액은 면역에 사용한 항원을 PBS로 10배희석(파장 660nm에서 흡광도 0.8)한 것을 이용하였다. 응집항원가는, 응집되는 샘플의 최대 희석배율의 역수로 표시하였다.50 microliters of each test solution and 50 microliters of antigen solution were mixed in a microplate, and left to stand at 37 ° C for 24 hours to check for coagulation. The antigen solution was obtained by diluting the antigen used for immunization with PBS 10 times (absorbance 0.8 at wavelength 660 nm). The aggregated antigenic value is expressed as the inverse of the maximum dilution factor of the sample to be aggregated.
응집항원가가 320이상의 계란을 할란하여 얻은 전란 및 난황 각 1kg을 균질기로 균질화하였다. 각각의 용액을 63℃, 3분간의 조건으로 살균을 행한 후, 분무건조로 분말을 조제하고, 헬리코박터 필로리에 대한 특이항체를 함유한 전란 및 난황분말 470g을 얻었다. 분무건조의 조건은, 송풍온도 145℃, 배풍온도 85℃에서 행하였다.1 kg of egg and egg yolk obtained by coagulating antigens of more than 320 eggs were homogenized with a homogenizer. Each solution was sterilized at 63 ° C. for 3 minutes, and then powder was prepared by spray drying to obtain 470 g of egg and egg yolk powder containing specific antibodies to Helicobacter pylori. The conditions of spray drying were performed at the blowing temperature of 145 degreeC, and the ventilating temperature of 85 degreeC.
얻어진 항체함유난황분말에 에탄올을 동량 첨가하여 탈지하였다. 지질은 2% 이하가 되게 탈지를 반복하여 실시하였다. 항원액 A에서 얻은 탈지 난황 분말을 시료분말 A라 하였다.An equal amount of ethanol was added to the obtained antibody-containing yolk powder for degreasing. Lipids were repeatedly degreased to be 2% or less. Defatted egg yolk powder obtained from the antigen solution A was referred to as sample powder A.
(3) 계란항체함유 조성물의 제조(3) Preparation of Egg Antibody-Containing Composition
얻어진 시료분말 A에 정제수 25.1%를 첨가하여 비교용 계란항체함유조성물(1)을 제조하고, 또 시료분말 A에 인지질(10%), 고과당(5%), 솔비톨(5%)을 첨가, 아래와 같은 비율로 정제수, 카테킨 및 GMP를 배합하고 균질기로 균질될 때까지 교반 후, 냉장보관하였다.25.1% purified water was added to the obtained sample powder A to prepare a comparative egg antibody-containing composition (1), and to the sample powder A, phospholipid (10%), high fructose (5%) and sorbitol (5%) were added. Purified water, catechin and GMP were combined in the following ratios and stirred until homogenized with a homogenizer, then refrigerated.
(시험예 1)(Test Example 1)
계란항체 함유조성물의 헬리코박터 필로리에 대한 제균효과Antibacterial Effect of Helicobacter Philophyllum Containing Egg Antibody-Containing Compositions
실시예 1에서 제조한 계란항체함유조성물을 헬리코박터 필로리에 감염된 시궁쥐에게 14일 동안 1일 1회 경구투여 하였다. 14일 경과후 부검하여 위점막에 유착된 헬리코박터 필로리 세포의 수를 아래와 같이 측정하였다.The egg antibody-containing composition prepared in Example 1 was orally administered once a day for 14 days to the rats infected with Helicobacter pylori. After 14 days, the number of Helicobacter pylori cells adhered to the gastric mucosa was measured as follows.
위의 조직을 PBS(pH 7.2)로 8회 세척후 균질화하였다. 선택배지(Poremedia H.pylori 분리배지, Eiken kagaku)에 접종한 후, 가스팩법으로 37℃에서 5일간 배양하였다.The stomach tissues were homogenized after 8 washes with PBS pH 7.2. After inoculation into selective medium (Poremedia H. pylori isolated medium, Eiken kagaku), and incubated for 5 days at 37 ℃ by the gas pack method.
도 1에서 나타난 결과와 같이, 계란항체함유조성물이 투여된 양에 의존하여 위내 헬리코박터 필로리의 수가 감소하는 경향을 나타내었다. 그 중에서 계란항체함유조성물 (2)가 가장 효과가 좋았다. 카테킨과 GMP의 함량 증가의 경우에도 위내 헬리코박터 필로리 수의 감소현상을 나타내었으나, 카테킨 함량 0.1중량% 초과첨가시 고미가 느껴져 풍미에 좋지 못하였으며, GMP의 경우에도 1 중량% 초과 첨가시 용해성이 문제가 되었다.As shown in FIG. 1, the number of helicobacter pylori in the stomach tended to decrease depending on the amount of the egg antibody-containing composition administered. Among them, the egg antibody-containing composition (2) was the most effective. In the case of increased catechin and GMP content, there was a decrease in the number of helicobacter pylori in the stomach, but when it was added more than 0.1% by weight of catechin, the taste was not good, and it was not good for flavor. It became a problem.
(시험예 2)(Test Example 2)
가공안정성시험Machining stability test
계란항체함유조성물(1),(2)에 60-72℃의 열을 5분간 가하고, 그 후 분말중의 항체활성을 측정하여 분말의 열 안정성을 검토하고, 동일한 방법으로 시료분말에 pH 3.2-4.5의 산성용액을 가하여 pH 안정성을 검토하였다. 그 결과를 표 1 및 표 2에 각각 나타내었다.The egg antibody-containing compositions (1) and (2) were heated at 60-72 ° C. for 5 minutes, and then the antibody activity in the powder was measured to examine the thermal stability of the powder. An acidic solution of 4.5 was added to check pH stability. The results are shown in Tables 1 and 2, respectively.
(시험예 3)(Test Example 3)
가공특성Processing characteristics
계란항체함유조성물(1),(2)를 사용하여, 아래와 같이 액상식품(요구르트)을 만들어, 난황액과 요구르트배양액의 분리상태를 비교했다.Using the egg antibody-containing compositions (1) and (2), liquid foods (yogurts) were prepared as follows, and the separation states of the yolk solution and the yogurt culture solution were compared.
제조한 식품의 난황성분 분리상황을 검토한 결과, 본 발명에 따른 계란 항체 함유 조성물을 포함하는 처방 1의 식품에서는 난황성분의 분리가 확인되지 않고 안정성을 유지하였으며 양호한 분산성과 용해성을 보였다.As a result of examining the separation status of the yolk component of the prepared food, in the food of the formula 1 containing the egg antibody-containing composition according to the present invention, the separation of the yolk component was not confirmed and the stability was maintained and good dispersibility and solubility were shown.
한편, 처방 2는 난황성분의 분리되어 부유되는 현상이 확인되었다. 또한, 관능평가에서도 처방 1의 식품에서 양호한 결과를 얻었다. 이러한 안정성 및 용해성의 향상으로 드링크 요구르트 등 액상 제품 응용도 가능해졌다.On the other hand, Formula 2 was confirmed that the separation of the egg yolk component floating. In addition, the sensory evaluation also showed satisfactory results with the food of prescription 1. This improvement in stability and solubility has enabled the application of liquid products such as drink yogurt.
(시험예 4)(Test Example 4)
상승효과 확인시험Synergy Confirmation Test
헬리코박터 필로리의 조제는 실시예 1과 같은 방법으로 하였다. 헬리코박터 필로리의 콜로니를 모아, 10mM, PBS pH 7.4로 세정하였다. 3,000×g에서 10분간 원심분리하여 모은 균을 다시 10mM PBS pH7.4에 현탁하면, 1ml에 약 2×102CFU쯤 된다.Preparation of Helicobacter pylori was carried out in the same manner as in Example 1. Colonies of Helicobacter pylori were collected and washed with 10 mM and PBS pH 7.4. The cells collected by centrifugation at 3,000 x g for 10 minutes are suspended again in 10 mM PBS pH 7.4, about 2 x 10 2 CFU in 1 ml.
0.2% 돼지 위점막 뮤신(Sigma사)용액으로 도포한 24웰 폴리스틸렌 플레이트에, 균액과 비교용 탈지난황분말액(10mg/ml), 상기 계란항체함유조성물(1), (2), 카테킨 조성물 및 GMP 조성물을 각각 1ml씩 첨가하고, 1시간 배양하고, 생리식염수에서 세정 후, 플레이트에 잔존하는 헬리코박터 필로리의 균수를, 같은 균이 생산하는 우레아제를 측정함으로써 산정하였다. 우레아제의 활성은 단위시간에 생성하는 우레아제량을 인도페놀법에 따라 파장 557nm의 흡광도를 구하였다.To a 24-well polystyrene plate coated with 0.2% swine gastric mucosa mucin (Sigma) solution, the comparison with the bacteria solution degreasing egg yolk powder (10mg / ml), the egg antibody-containing composition (1), (2), catechin composition and 1 ml of each GMP composition was added, incubated for 1 hour, washed with physiological saline, and the number of bacteria of Helicobacter pylori remaining on the plate was calculated by measuring the urease produced by the same bacteria. For the activity of urease, the absorbance having a wavelength of 557 nm was determined by the indophenol method.
대조물로는 시판 난황에서 얻은 탈지분말을 이용하고, 위와 같은 방법으로 부착량을 조사하고, 그 값을 1로 하였을 때의 측정결과를 표 3 및 도 3 에 나타냈다.As a control, using a skim powder obtained from a commercial egg yolk, the amount of adhesion was investigated in the same manner as above, and the measurement results when the value was 1 were shown in Table 3 and FIG. 3.
상기의 결과에서, 비교용 탈지 난황 분말액과 계란항체함유조성물(1), (3), (4), (5), 카테킨 조성물, GMP 조성물 등에 비하여 본원 발명에 따른 계란항체함유조성물(2)에서 훨씬 개선된 접착저해효과가 확인되었다.In the above results, compared with the comparative skim egg yolk powder solution and egg antibody-containing composition (1), (3), (4), (5), catechin composition, GMP composition, etc., the egg antibody-containing composition (2) according to the present invention Significantly improved adhesion inhibitory effect was observed in.
(제조예 1)(Manufacture example 1)
위염, 위·십이지장궤양 예방식품의 조제Preparation of foods to prevent gastritis and stomach and duodenal ulcer
위염, 위·십이지장궤양 예방식품을 아래와 같이 처방하여 조제하였다.Gastritis, gastric and duodenal ulcer foods were prescribed as follows.
1) 위염, 위궤양 및 십이지장궤양 예방 요구르트1) Yogurt to prevent gastritis, gastric ulcer and duodenal ulcer
2) 위염, 위궤양 및 십이지장궤양 예방 혼합 분유2) Mixed milk powder to prevent gastritis, gastric ulcer and duodenal ulcer
3) 위염, 위궤양 및 십이지장궤양 예방 아이스크림3) Prevention of gastritis, gastric ulcer and duodenal ulcer
본 발명에 따르면, 헬리코박터 필로리에 대한 제균효과가 우수하여 위염, 위궤양 및 십이지장궤양 등의 예방 효과가 클 뿐 아니라, 내열성, 내산성, 용해성, 분산성 및 가공성이 향상된 난황 유래 항체 조성물, 및 이를 함유하는 식품을 얻을 수 있다.According to the present invention, the yolk-derived antibody composition having excellent bactericidal effect on Helicobacter pylori, which is effective in preventing gastritis, gastric ulcer and duodenal ulcer, as well as heat resistance, acid resistance, solubility, dispersibility and processability, and containing the same You can get food.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0001763A KR100392904B1 (en) | 2001-01-12 | 2001-01-12 | Composition containing egg yolk antibody, and food containing it |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2001-0001763A KR100392904B1 (en) | 2001-01-12 | 2001-01-12 | Composition containing egg yolk antibody, and food containing it |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020063936A KR20020063936A (en) | 2002-08-07 |
KR100392904B1 true KR100392904B1 (en) | 2003-07-28 |
Family
ID=27691488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2001-0001763A KR100392904B1 (en) | 2001-01-12 | 2001-01-12 | Composition containing egg yolk antibody, and food containing it |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100392904B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100485269B1 (en) * | 2002-10-22 | 2005-04-29 | 주식회사 에그 바이오택 | The production method of kimchi containing immunoglobulin y for e.coli, helicobacter pylori and thereof kimchi |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100501205B1 (en) * | 2001-09-24 | 2005-07-18 | 주식회사 에그 바이오택 | THE METHOD FOR SOYBEAN PASTE CONTAINING anti-E.coli AND anti-Helicobacter pylori SPECIFIC IgY |
KR20030026502A (en) * | 2001-09-26 | 2003-04-03 | 배만종 | A production method of common egg, native egg, blue egg have various skill |
AT512342B1 (en) * | 2011-12-19 | 2013-10-15 | Sciotec Diagnostic Technologies Gmbh | COMPOSITION |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05139972A (en) * | 1991-11-25 | 1993-06-08 | Taiyo Kagaku Co Ltd | Composition for preventing gastritis and gastric or duodenal ulcer |
KR19980081323A (en) * | 1997-04-11 | 1998-11-25 | 도꼬로히데오 | Specific antibodies used in the manufacture of pharmaceutical compositions for the prevention or treatment of gastritis, gastric ulcer and duodenal ulcer |
KR20000049499A (en) * | 2000-03-31 | 2000-08-05 | 이은선 | A METHOD OF PREPARING FERMENTED MILK USING EGG YOLK CONTAINING ANTI-Helicobacter pylori CHICKEN IgY |
JP2001017122A (en) * | 1999-07-12 | 2001-01-23 | Taiyo Kagaku Co Ltd | Food for preventing inflammation of digestive system |
KR20020032890A (en) * | 2000-10-27 | 2002-05-04 | 이남형 | The method for production of egg containing anti-E.coli IgY and anti-Helicobacter pylori IgY simultaneously, and egg, yogurt and ice-cream containing specific IgY for anti-E.coli and anti-Helicobacter pylori |
-
2001
- 2001-01-12 KR KR10-2001-0001763A patent/KR100392904B1/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05139972A (en) * | 1991-11-25 | 1993-06-08 | Taiyo Kagaku Co Ltd | Composition for preventing gastritis and gastric or duodenal ulcer |
KR19980081323A (en) * | 1997-04-11 | 1998-11-25 | 도꼬로히데오 | Specific antibodies used in the manufacture of pharmaceutical compositions for the prevention or treatment of gastritis, gastric ulcer and duodenal ulcer |
JP2001017122A (en) * | 1999-07-12 | 2001-01-23 | Taiyo Kagaku Co Ltd | Food for preventing inflammation of digestive system |
KR20000049499A (en) * | 2000-03-31 | 2000-08-05 | 이은선 | A METHOD OF PREPARING FERMENTED MILK USING EGG YOLK CONTAINING ANTI-Helicobacter pylori CHICKEN IgY |
KR20020032890A (en) * | 2000-10-27 | 2002-05-04 | 이남형 | The method for production of egg containing anti-E.coli IgY and anti-Helicobacter pylori IgY simultaneously, and egg, yogurt and ice-cream containing specific IgY for anti-E.coli and anti-Helicobacter pylori |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100485269B1 (en) * | 2002-10-22 | 2005-04-29 | 주식회사 에그 바이오택 | The production method of kimchi containing immunoglobulin y for e.coli, helicobacter pylori and thereof kimchi |
Also Published As
Publication number | Publication date |
---|---|
KR20020063936A (en) | 2002-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brumini et al. | Whey proteins and their antimicrobial properties in donkey milk: a brief review | |
Uruakpa et al. | Colostrum and its benefits: a review | |
El-Loly et al. | Lactoferrin in relation to biological functions and applications: A | |
ES2249207T3 (en) | OSEA RESORTION SUPPRESSION AGENT. | |
JP5718254B2 (en) | Method for producing lactoferrin | |
Tripathi et al. | Bioactive compounds of colostrum and its application | |
KR20030051822A (en) | Colostrum-based Composition | |
Kaskous et al. | Bioactive properties of minor camel milk ingredients-An overview | |
CN113056207A (en) | Natural whey protein for improving intestinal maturation | |
CN112996396A (en) | Natural whey protein for the treatment and/or prevention of intestinal infections | |
JP3998293B2 (en) | Helicobacter pylori inhibitor | |
EP1322669B1 (en) | Stabilisation of immunoglobulins at low pH by adding cereals or oatmeal soup or oat flour | |
KR100392904B1 (en) | Composition containing egg yolk antibody, and food containing it | |
AU2006242106A1 (en) | Transfer factor preparations and associated methods | |
JP3072353B2 (en) | Food for preventing gastritis, stomach or duodenal ulcer | |
US20050096262A1 (en) | Helicobacter pylori adhesion inhibitor | |
JP2001017122A (en) | Food for preventing inflammation of digestive system | |
EP0930316B1 (en) | Oral product for the prevention and treatment of infectious gastroenteritides in calves | |
WO1998005221A1 (en) | Drinkable, acid nutrient composition with long shelf life and health-promoting action | |
Panwar | Biologically active components of human and bovine milk as potent antimicrobial agents | |
KR20020093410A (en) | Functional silken tofu and method for preparing thereof | |
Keyvan | Milk Quality for Development of Probiotic and Prebiotic Dairy Foods | |
Fayed | Healthy multifunctional spectra of milk glycoproteins and their fragments-a review article | |
JP4306828B2 (en) | Protective agent against pathogenic bacteria | |
KR20030033721A (en) | Foodstuff containing lactic acid bacteria having anti-helicobacter pylori activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130620 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20140605 Year of fee payment: 12 |
|
LAPS | Lapse due to unpaid annual fee |